Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.87
- Piotroski Score 3.00
- Grade Buy
- Symbol (RNAC)
- Company Cartesian Therapeutics, Inc.
- Price $15.91
- Changes Percentage (-6.41%)
- Change -$1.09
- Day Low $15.55
- Day High $17.04
- Year High $42.60
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $43.00
- High Stock Price Target $45.00
- Low Stock Price Target $40.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-219,710,000
Income Statement
Quarterly
Annual
Latest News of RNAC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Port Talbot: steel town braces for shutdown of its last blast furnace
Port Talbot faces job losses and closure of blast furnace, ending traditional steelmaking. Transition to greener electric arc furnace will cost thousands of jobs and impact local community, marking th...
By The Guardian | 23 hours ago -
End of an era as last blast furnace shuts down at Port Talbot steelworks
The closure of blast furnace number four at Tata Steel UK's Port Talbot plant will result in 2,000 job losses. The transition to an electric arc furnace aims to reduce CO2 emissions by 1.5%....
By Yahoo! Finance | 1 day ago -
Larnach and Wallner get RBI singles in 12th, Twins beat Red Sox 4-2
Minnesota Twins defeated Boston Red Sox 4-2 with RBI singles from Larnach and Wallner in 12th inning. Twins lead in AL wild-card race with sixth win in last 17 games. Red Sox rookie Fitts made history...
By CBS News | 1 week ago
